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Prolyl oligopeptidase inhibition reduces PolyQ aggregation and 
improves cell viability in cellular model of Huntington’s disease
































proteasome	 system	causing	 a	 further	 increase	 in	 the	 intracellular	







ulate	 autophagy.5	KYP‐2047	 is	 a	 small‐molecule	 inhibitor	 of	PREP	
having	a	disease‐modifying	effect	in	the	alpha‐synuclein	(aSyn)	mod‐
els	of	Parkinson´s	disease	(for	review,	see	Ref.6).	We	have	shown	that	
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3  | RESULTS AND DISCUSSION
3.1 | PREP inhibition attenuates mHtt 103Q toxicity 
after proteasomal inhibition




Increasing	 the	 concentration	 of	 lactacystin	 reduced	 cell	 viability	
specifically	of	103Q‐expressing	cells	using	the	LDH	assay	and	this	
could	be	reversed	using	1	µmol/L	KYP‐2047	(Figure	1A,C,E;	P	<	.05,	





Data	 show	 that	 high‐dose	 of	 lactacystin	 is	 toxic	 for	 cells	 even	
without	 polyQ	 overexpression.	 However,	 significant	 and	 dose‐de‐
pendent	 toxicity	 in	 LDH	 assay	 was	 seen	 only	 in	 103Q‐expressing	






3.2 | PREP inhibition reduces mHtt 103Q 
aggregates in cells
103Q	 cells	 were	 immunostained	 to	 detect	 polyQ	 aggregates	 in	
control	 and	 lactacystin‐treated	 cells.	 ICC	 showed	 that	 untreated	
103Q‐expressing	cells	had	a	diffuse	staining	of	mHtt,	while	addition	
of	10	µmol/L	lactacystin	for	48	hours	induced	the	formation	of	GFP‐




Next,	 we	 performed	 immunoblots	 on	 cell	 fractions	 obtained	
from	25Q‐	and	103Q‐expressing	cells.	For	this,	cells	were	fractioned	
into	 soluble	 and	 SDS‐soluble/insoluble	 fractions	 as	 described	 in	
Methods.	There	was	a	significant	increase	in	high‐molecular‐weight	
(HMW)	 mHtt	 particles,	 representing	 insoluble	 aggregates,	 in	 the	
103Q	expression	 but	 not	 in	 the	 25Q‐expressing	 cells	 (Figure	 2D).	
In	contrast,	the	amount	of	soluble	mHtt	levels	remained	largely	un‐
changed	(Figure	S1).






not	 significantly	 changed	 although	 KYP‐2047	 increased	 it	 after	





levels.	Additionally,	we	studied	 the	 levels	of	p62	 in	 soluble	 frac‐
tion	but	no	changes	were	observed	(Figure	S1).	Together,	this	sug‐
gests	that	lactacystin	induced	mainly	the	aggregation	of	insoluble	






that	 pharmacological	 activation	 of	 autophagy	 may	 under	 certain	
conditions	cause	apoptosis	rendering	them	less	attractive	for	clin‐
ical	use.4	However,	 the	concept	of	PREP	 inhibition	has	been	con‐
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